Genes are Natural, and Not Patentable
Fascinating turn of events on Friday, when the DOJ: said on Friday that human and other genes should not be eligible for patents because they are part of nature This…
Menu
Orphan Drugs & Venture Capital Backed Companies
The October, 2010 issue of Life Science Leader has an interesting article entitled Orphan Drugs: Big Pharma's Next Act? The premise is that Big Pharma is turning towards orphan drug…
Biosimilars, Champagne, and Beer
A former business development colleague of mine used to refer to some prospects as having "champagne tastes with beer wallets." His meaning was clear. It's one thing to want champagne,…
Lilly to close Singapore drug discovery center
Today we learned that Lilly will close their Singapore R&D facility. This facility was focused on drug discovery in cancer and diabetes. I leave it to the powers that be…
Is FDA Jazzed about Fibromyalgia? Not so much…
It is regrettable that the FDA issued a complete response letter to Jazz Pharmaceuticals for JZP-6. If there is a disease that can use some innovation, it's fibromyalgia. The CRL…
Physicians don’t email patients
Physicians typically don't interact with their patients via email. This is understandable and quite interesting, as physicians tend to be quite computer savvy. A recent report explains the reasons why this is the case.
Drug Delivery is Dead? Hardly!
Drug delivery is not dead! In fact, drug delivery can ba a valuable tool for developing and commercializing drugs faster and at lower cost versus NCEs.
Why is Pain such a Pain?
Late last month, Johnson and Johnson (J&J) announced the results of Phase III clinical trials comparing tapentadol extended release compared to oxycodone controlled release and placebo. In this study, J&J…
GSK Spinout – Great, but let’s be realistic
Today we read the news that GSK will spin out a team of fourteen scientists and patents into a standalone company. Convergence Pharmaceuticals will focus on the development of pain…
FDA wants more from J&J
Chronic pain patients have to wait even longer for access to twice-daily tapentadol.